Inhaled Amikacin Treatment for Nontuberculous Mycobacterial Lung Disease

Inclusion Criteria: 1. Diagnosis of NTM lung lung disease in accordance with the 2007 ATS/IDSA criteria. 2. MAC lung disease with persistent sputum culture positive after 6 months of standard treatment 3. M. abscessus lung disease with persistent sputum culture positive after 6 months of standard treatment 4. New case of M. abscessus pulmonary disease after completion of initial 4 weeks intravenous antibiotics treatment Exclusion Criteria: 1. Subjects with negative sputum culture before starting of this study 2. Forced expiratory volume in 1 second (FEV1) \<30% of predicted at screening. 3. Positive in HIV test. 4. Subjects with chronic renal insufficient state (serum creatinine level is more than 2.0 mg/dL) 5. Subjects with decreased liver function (serum total bilirubin level is more than 2 mg/dL or AST or ALT are more than 1.5 times of upper normal limits) 6. Active any malignancy requiring chemotherapy or radiation therapy within one year prior to screening. 7. Subjects with history of allergy to amikacin. 8. Subjects with pregnant state or women of childbearing age with no appropriate contraception.